MARAbio launched the MAR-Autism™ Test, a blood-based test for identifying specific maternal autoantibody patterns associated with Maternal Autoantibody-Related autism, designed for mothers with children diagnosed with autism or showing signs of autism.
Published
Signal category
Products & Services
Quote
“The MAR-Autism™ Test identifies these specific autoantibody patterns using a blood sample from the mother.”
— MARAbio team
Company
MARAbio
Our vision is a world in which the most severe effects of autism do not occur.
- Industry
- Biotechnology Research
- Location
- Salt Lake City, US
- Company size
- 21 employees
We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.
Founded 2016